US2004157889A1PendingUtilityA1
Method of treating of demyelinating diseases or conditions
Est. expiryFeb 15, 2021(expired)· nominal 20-yr term from priority
A61P 9/00A61P 43/00A61P 37/00A61P 9/10A61P 35/00A61P 25/00A61P 27/02A61P 3/00A61P 25/04A61P 25/02A61P 29/00A61P 25/28A61P 19/02A61P 19/00A61P 17/02A61P 19/08A61P 13/10A61P 13/02A61P 13/00A61K 31/4439
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A method of treating Demyelinating Diseases said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I
wherein
m is 0, 1 or 2;
n is 0, 1 or 2;
p is 0 or 1;
each R is independently hydrogen, halogen, trifluoromethyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, benzyloxy, hydroxy, nitro or amino;
each R 1 is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkanoyl, halogen, cyano, —C(O)C 1 -C 6 alkyl, —C 1 -C 6 alkyleneCN, —C 1 -C 6 alkyleneNR′R″ wherein R′ and R″ are each independently hydrogen or C 1 -C 6 alkyl,
—C 1 -C 6 alkyleneOC(O)C 1 -C 6 alkyl, or —CH(OH)R 4 wherein R 4 is hydrogen or C 1 -C 6 alkyl;
R 2 is hydrogen, C 1 -C 6 alkyl optionally substituted with halogen, hydroxy or benzyloxy, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl,
—CO 2 C 1 -C 6 alkyl, or —R 5 —NR′ R″ wherein R 5 is C 1 -C 6 alkylene, C 1 -C 6 alkenylene or C 1 -C 6 alkynylene and R′ and R″ are each independently hydrogen, C 1 -C 6 alkyl or alternatively the group —NR′R″ as a whole is 1-pyrrolidinyl; and
R 3 is hydrogen, nitro, amino, halogen, C 1 -C 6 alkoxy, hydroxy or C 1 -C 6 alkyl
or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 wherein R is hydrogen, halogen, trifluoromethyl, or C 1 -C 6 alkyl; R 1 is hydrogen or C 1 -C 6 alkyl; R 2 is hydrogen or C 1 -C 6 alkyl; R 3 is hydrogen, C 1 -C 6 alkyl or halogen; and p is 0.
3 . The method of claim 1 wherein the Demyelinating Disease is multiple sclerosis.
4 . The method of claim 2 wherein the compound has the following formula
5 . The method of claim 4 wherein the Demyelinating Disease is multiple sclerosis.
6 . A method of treating Demyelinating Conditions said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 .
7 . The method of claim 6 wherein R is hydrogen, halogen, trifluoromethyl, or C 1 -C 6 alkyl; R 1 is hydrogen or C 1 -C 6 alkyl; R 2 is hydrogen or C 1 -C 6 alkyl; R 3 is hydrogen, C 1 -C 6 alkyl or halogen; and p is 0.
8 . The method of claim 6 wherein the Demyelinating Condition is Spinal Cord Injury.
9 . The method of claim 6 wherein the Demyelinating Condition is Traumatic Brain Injury.
10 . The method of claim 6 wherein the Demyelinating Condition is Stroke.
11 . The method of claim 7 wherein the compound has the following formula
12 . The method of claim 11 wherein the Demyelinating Condition is Spinal Cord Injury.
13 . The method of claim 11 wherein the Demyelinating Condition is Traumatic Brain Injury.
14 . The method of claim 11 wherein the Demyelinating Condition is Stroke.
15 . A method of Stroke Rehabilitation said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 .
16 . The method of claim 14 wherein R is hydrogen, halogen, trifluoromethyl, or C 1 -C 6 alkyl; R 1 is hydrogen or C 1 -C 6 alkyl; R 2 is hydrogen or C 1 -C 6 alkyl; R 3 is hydrogen, C 1 -C 6 alkyl or halogen; and p is 0.
17 . The method of claim 16 wherein the compound has the following formula
18 . A method of blocking the potassium channel in a patient in need thereof by administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 .
19 . The method of claim 18 wherein R is hydrogen, halogen, trifluoromethyl, or C 1 -C 6 alkyl; R 1 is hydrogen or C 1 -C 6 alkyl; R 2 is hydrogen or C 1 -C 6 alkyl; R 3 is hydrogen, C 1 -C 6 alkyl or halogen; and p is 0.
20 . The method of claim 19 wherein the compound has the following formula
21 . The method of claim 2 wherein the compound has the following formula
22 . The method of claim 7 wherein the compound has the following formula
23 . The method of claim 22 wherein the demyelinating condition is Spinal Cord Injury.
24 . The method of claim 22 wherein the demyelinating condition is Traumatic Brain Injury.
25 . The method of claim 22 wherein the demyelinating condition is Stroke.
26 . A method of treating Neuropathic Pain said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 .
27 . The method of claim 26 wherein the compound has the following formula:
28 . A method of treating Bladder Irritation said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 .
29 . The method of claim 28 wherein the compound has the following formula:
30 . A method of treating Over Active Bladder said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 .
31 . The method of claim 30 wherein the compound has the following formula:
32 . A method of treating chemokine-induced pain said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 .
33 . The method of claim 32 wherein the compound has the following formula:Join the waitlist — get patent alerts
Track US2004157889A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.